16 sep 2019
CPHI Middle East & Africa 2019
Shandong Kexing Bioproducts Co., Ltd.

Shandong Kexing Bioproducts Co., Ltd.

Exhibitor at CPHI Middle East & Africa 2019 stand P83

About us

Shandong Kexing Bioproducts integrates R&D, manufacture, and sales of biopharmaceuticals. 
Its production site offers Recombinant Human Erythropoietin Injection(EPO), Recombinant Human Granulocyte Colony-stimulating Factor Injection(rh-G-CSF)Filgrastim, and Combined Clostridium Butyricum and Bifidobacterium Powders, Live for clinical and commercial use. I
The company develops recombinant genetic biological drugs and micro-ecological preparation, to serve the clinical treatment needs of kidney diseases, tumor, and gastrointestinal diseases. It has become a leading player in China's biopharmaceutical industry after more than 20 years of development.
- No.1 Chinese producer of Recombinant Human Erythropoietin Injection(CHO Cell)
- One of leading bio-pharmaceutical suppliers in China
- EPSINO is the first EPO Product put in Chinese market
- The only EPO product free of human albumin in China
- First-class G-CSF
- Non-toxic certain bacteria combination
- Diversity of target markets for treatment of renal disease, tumors, gastrointestinal tract disease
- Advanced market- oriented R&D capabilities
- Mature domestic marketing network
- High-efficient international sales team
- Improved market-oriented management team
- Strict quality management system to ensure safety,effectiveness and stability

Specs about this supplier

Sales markets Eastern Europe; Middle East; Asia; Africa; Central/South America
Affiliated categories: Biopharmaceuticals (general category) |Injectables |Parenterals More

Products featured at CPHI Middle East & Africa 2019

Shandong Kexing Bioproducts Co., Ltd.

Event information

CPHI Middle East & Africa 2019

16 -18 September 2019 ADNEC, Abu Dhabi, UAE Visit us at stand P83